Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. In a release it put out late Tuesday ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company has been on a ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Stock market analysts have conflicting opinions about the market value of this genetic testing business. Worth more than $10 billion at its peak, beaten-down Invitae could provide huge returns if it ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Despite efforts, Invitae shares ...